Comments
Loading...

Biohaven Analyst Ratings

BHVNNYSE
Logo brought to you by Benzinga Data
$29.50
0.642.22%
Pre-Market: 5:10 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$148.50
Lowest Price Target1
$24.00
Consensus Price Target1
$68.82

Biohaven Analyst Ratings and Price Targets | NYSE:BHVN | Benzinga

Biohaven Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Biohaven Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Oct 24
5
Nov 24
3
Dec 24
1
Feb
4
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
JP Morgan
HC Wainwright & Co.
RBC Capital
Deutsche Bank

1calculated from analyst ratings

Analyst Ratings for Biohaven

Buy NowGet Alert
03/07/2025Buy NowMorgan Stanley
Terence Flynn66%
$69 → $63MaintainsOverweightGet Alert
03/05/2025Buy NowJP Morgan
Tessa Romero62%
$72 → $68MaintainsOverweightGet Alert
03/04/2025Buy NowHC Wainwright & Co.
Douglas Tsao52%
$54 → $54ReiteratesBuy → BuyGet Alert
03/04/2025Buy NowRBC Capital
Leonid Timashev47%
$61 → $61ReiteratesOutperform → OutperformGet Alert
02/11/2025Buy NowDeutsche Bank
David Hoang42%
→ $65Initiates → BuyGet Alert
12/17/2024Buy NowCantor Fitzgerald
Charles Duncan73%
ReiteratesOverweight → OverweightGet Alert
12/17/2024Buy NowHC Wainwright & Co.
Douglas Tsao52%
$59 → $59ReiteratesBuy → BuyGet Alert
12/04/2024Buy NowRBC Capital
Leonid Timashev47%
$58 → $61ReiteratesOutperform → OutperformGet Alert
11/26/2024Buy NowHC Wainwright & Co.
Douglas Tsao52%
$59 → $59ReiteratesBuy → BuyGet Alert
11/25/2024Buy NowRBC Capital
Leonid Timashev47%
$66 → $58MaintainsOutperformGet Alert
11/14/2024Buy NowHC Wainwright & Co.
Douglas Tsao52%
$59 → $59ReiteratesBuy → BuyGet Alert
11/13/2024Buy NowTD Cowen
Tyler Van Buren48%
$55 → $75MaintainsBuyGet Alert
11/13/2024Buy NowRBC Capital
Leonid Timashev47%
$68 → $66MaintainsOutperformGet Alert
10/23/2024Buy NowCantor Fitzgerald
Charles Duncan73%
Reiterates → OverweightGet Alert
10/04/2024Buy NowCantor Fitzgerald
Charles Duncan73%
Reiterates → OverweightGet Alert
10/03/2024Buy NowJP Morgan
Tessa Romero62%
$55 → $68MaintainsOverweightGet Alert
09/24/2024Buy NowBernstein
William Pickering45%
$55 → $66MaintainsOutperformGet Alert
09/24/2024Buy NowB of A Securities
Jason Gerberry63%
$52 → $62MaintainsBuyGet Alert
09/24/2024Buy NowRBC Capital
Leonid Timashev47%
$59 → $68MaintainsOutperformGet Alert
09/24/2024Buy NowCantor Fitzgerald
Charles Duncan73%
Reiterates → OverweightGet Alert
09/24/2024Buy NowHC Wainwright & Co.
Douglas Tsao52%
$59 → $59ReiteratesBuy → BuyGet Alert
09/23/2024Buy NowLeerink Partners
Marc Goodman74%
$55 → $60MaintainsOutperformGet Alert
09/23/2024Buy NowPiper Sandler
Christopher Raymond57%
$66 → $76MaintainsOverweightGet Alert
09/23/2024Buy NowBaird
Brian Skorney57%
$58 → $60MaintainsOutperformGet Alert
09/16/2024Buy NowJefferies
Amy Li5%
→ $57Initiates → BuyGet Alert
09/04/2024Buy NowBernstein
William Pickering45%
→ $55Initiates → OutperformGet Alert
09/04/2024Buy NowRBC Capital
Leonid Timashev47%
$59 → $59ReiteratesOutperform → OutperformGet Alert
08/19/2024Buy NowCantor Fitzgerald
Charles Duncan73%
Reiterates → OverweightGet Alert
08/13/2024Buy NowUBS
Ashwani Verma49%
$55 → $54MaintainsBuyGet Alert
08/12/2024Buy NowCantor Fitzgerald
Charles Duncan73%
Reiterates → OverweightGet Alert
07/24/2024Buy NowMorgan Stanley
Terence Flynn66%
→ $58Initiates → OverweightGet Alert
06/18/2024Buy NowRBC Capital
Leonid Timashev47%
$59 → $59ReiteratesOutperform → OutperformGet Alert
05/30/2024Buy NowHC Wainwright & Co.
Douglas Tsao52%
$59 → $59ReiteratesBuy → BuyGet Alert
05/30/2024Buy NowCantor Fitzgerald
Charles Duncan73%
Reiterates → OverweightGet Alert
05/13/2024Buy NowHC Wainwright & Co.
Douglas Tsao52%
$63 → $59MaintainsBuyGet Alert
04/23/2024Buy NowUBS
Ashwani Verma49%
$59 → $60MaintainsBuyGet Alert
04/18/2024Buy NowCantor Fitzgerald
Charles Duncan73%
Reiterates → OverweightGet Alert
04/10/2024Buy NowCantor Fitzgerald
Charles Duncan73%
Reiterates → OverweightGet Alert
04/09/2024Buy NowRBC Capital
Leonid Timashev47%
$61 → $61ReiteratesOutperform → OutperformGet Alert
03/04/2024Buy NowHC Wainwright & Co.
Douglas Tsao52%
$50 → $63MaintainsBuyGet Alert
03/01/2024Buy NowRBC Capital
Leonid Timashev47%
$62 → $61MaintainsOutperformGet Alert
03/01/2024Buy NowTD Cowen
Tyler Van Buren48%
$35 → $55MaintainsOutperformGet Alert
02/23/2024Buy NowJP Morgan
Tessa Romero62%
$32 → $56MaintainsOverweightGet Alert
02/16/2024Buy NowRBC Capital
Leonid Timashev47%
→ $62Initiates → OutperformGet Alert
02/06/2024Buy NowUBS
Ashwani Verma49%
→ $59Initiates → BuyGet Alert
12/22/2023Buy NowHC Wainwright & Co.
Douglas Tsao52%
→ $50Initiates → BuyGet Alert
12/08/2023Buy NowBaird
Brian Skorney57%
→ $58Initiates → OutperformGet Alert
11/20/2023Buy NowJP Morgan
Tessa Romero62%
$26 → $32MaintainsOverweightGet Alert
11/15/2023Buy NowPiper Sandler
Christopher Raymond57%
$29 → $36MaintainsOverweightGet Alert
08/16/2023Buy NowJP Morgan
Tessa Romero62%
$27 → $24MaintainsOverweightGet Alert
07/17/2023Buy NowCantor Fitzgerald
Charles Duncan73%
→ $31ReiteratesOverweight → OverweightGet Alert
06/06/2023Buy NowBTIG
Thomas Shrader43%
$24 → $24Reiterates → BuyGet Alert
04/04/2023Buy NowCantor Fitzgerald
Charles Duncan73%
$27 → $31MaintainsOverweightGet Alert
01/24/2023Buy NowSVB Leerink
Marc Goodman74%
→ $24Initiates → OutperformGet Alert
01/04/2023Buy NowJP Morgan
Tessa Romero62%
→ $23Initiates → OverweightGet Alert
12/02/2022Buy NowBTIG
Thomas Shrader43%
→ $24Initiates → BuyGet Alert
10/26/2022Buy NowPiper Sandler
Christopher Raymond57%
$23 → $21MaintainsOverweightGet Alert
10/12/2022Buy NowPiper Sandler
Christopher Raymond57%
→ $23Initiates → OverweightGet Alert
08/19/2022Buy NowPiper Sandler
Christopher Raymond57%
DowngradeOverweight → NeutralGet Alert
08/08/2022Buy NowWedbush
Laura Chico47%
→ $148.5DowngradeOutperform → NeutralGet Alert
05/11/2022Buy NowHC Wainwright & Co.
Douglas Tsao52%
DowngradeBuy → NeutralGet Alert
05/11/2022Buy NowMorgan Stanley
Jeffrey Hung56%
$146 → $148.5MaintainsEqual-WeightGet Alert
05/11/2022Buy NowSVB Leerink
Marc Goodman74%
DowngradeOutperform → Market PerformGet Alert
04/06/2022Buy NowMorgan Stanley
Jeffrey Hung56%
$148 → $146MaintainsEqual-WeightGet Alert

FAQ

Q

What is the target price for Biohaven (BHVN) stock?

A

The latest price target for Biohaven (NYSE:BHVN) was reported by Morgan Stanley on March 7, 2025. The analyst firm set a price target for $63.00 expecting BHVN to rise to within 12 months (a possible 113.56% upside). 39 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Biohaven (BHVN)?

A

The latest analyst rating for Biohaven (NYSE:BHVN) was provided by Morgan Stanley, and Biohaven maintained their overweight rating.

Q

When was the last upgrade for Biohaven (BHVN)?

A

There is no last upgrade for Biohaven

Q

When was the last downgrade for Biohaven (BHVN)?

A

The last downgrade for Biohaven Ltd happened on August 19, 2022 when Piper Sandler changed their price target from N/A to N/A for Biohaven Ltd.

Q

When is the next analyst rating going to be posted or updated for Biohaven (BHVN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biohaven, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biohaven was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.

Q

Is the Analyst Rating Biohaven (BHVN) correct?

A

While ratings are subjective and will change, the latest Biohaven (BHVN) rating was a maintained with a price target of $69.00 to $63.00. The current price Biohaven (BHVN) is trading at is $29.50, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch